Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EC1169 in metastatic castration-resistant prostate cancer
NCT02202447Phase 1Completed
- Sponsor
- Endocyte
- Start
- May 2014
- Primary completion
- Nov 2018
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EC1169 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Endocyte. Primary endpoints: Maximum Tolerated Dose at 21 days and Radiographic Progression-Free Survival at 27 weeks. Started May 2014; status: completed.
02
Drugs
EC1169
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02202447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02202447.